search
Back to results

Safety and Efficacy of Topical Cream for Post-inflammatory Hyperpigmentation Skin Among Malaysians

Primary Purpose

Healthy

Status
Recruiting
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
Topical cream Z for PIH
Sponsored by
Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Healthy focused on measuring Aesthetic, Cosmetic, Post-inflammatory hyperpigmentation (PIH)

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Malaysia citizen Healthy adult, aged between 18 to 40 years old. Participants who have post-inflammatory hyperpigmentation on skin Exclusion Criteria: Participants with skin disorders such as skin infection or skin inflammation. Participants who have undergone any skin and cosmetic treatments such as dermal fillers, botox, laser, chemical peels within the last 3 months. Participant who is taking isotretinoin for the past 6 or 12 months and immunocompromised patients. Pregnant, breastfeeding women or planned for pregnancy during the study period.

Sites / Locations

  • Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) CentreRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Topical cream for PIH

Arm Description

The topical cream contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract.

Outcomes

Primary Outcome Measures

Change in skin spot level
Skin spot will be assessed using JANUS III skin analyzer.
Change in hyperpigmentation score
The hyperpigmented skin area will be assessed based on Modified Melasma Area and Severity Index (mMASI) Score. Scoring system of mMASI score: A, Area of involvement is rated from 0 to 6: (0 indicates absent, 1=<10%, 2= 10% to 90%, 3= 30%-49%, 4= 50%-69%, 5= 70% to 89%, 6=90% to 100%). D, Darkness is rated from 0 to 4: 0= absent, 1=slight hyperpigmentation, 2= mild hyperpigmentation, 3= marked hyperpigmentation, 4=severe hyperpigmentation. Total mMASI score range is 0 (clear) to 24 (most severe melasma) and calculated by adding scores (A and D) for 4 areas of the face. The formula for mMASI score = 0.3×A(forehead)×D (forehead)+0.3×A (left malar) ×D (left malar) + 0.3×A(right malar)×D (right malar)+0.1×A(chin)×D (chin).
Adverse effect after using the topical cream.
Based on adverse effect occurrence on participants that occur during study period (20 weeks)

Secondary Outcome Measures

Participant satisfaction after using the topical cream for 20 weeks.
Participation satisfaction will be evaluated using the Physician Global Assessment (PGA) survey. The subjective score of changes in skin conditions including skin wrinkles, dryness, smoothness, moisturizing and brightening effect will be graded as follows: very satisfied, satisfied, neutral, dissatisfied, very dissatisfied.

Full Information

First Posted
August 1, 2023
Last Updated
August 8, 2023
Sponsor
Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT05986123
Brief Title
Safety and Efficacy of Topical Cream for Post-inflammatory Hyperpigmentation Skin Among Malaysians
Official Title
Safety and Efficacy of Topical Cream Containing Natural Plant Extracts, Niacinamide, and Arbutin for Post-inflammatory Hyperpigmentation Skin Among Malaysians
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2023 (Actual)
Primary Completion Date
July 31, 2024 (Anticipated)
Study Completion Date
September 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study was conducted to determine safety and efficacy of topically applied cream containing combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract for its skin brightening effect on post-inflammatory hyperpigmentation among the Malaysian population. The study duration is 20 weeks and the skin assessment will be carried out at baseline, week 4, week 8, week 12, week 16 and week 20.The main questions this study aims to answer are: To determine the efficacy of topical cream containing natural plant extracts, niacinamide, and arbutin for post-inflammatory hyperpigmentation among Malaysians. To investigate the safety of topical cream containing natural plant extracts, niacinamide, and arbutin for post-inflammatory hyperpigmentation among Malaysians. To assess the participants satisfaction of using topical cream containing natural plant extracts, niacinamide, and arbutin for post-inflammatory hyperpigmentation among Malaysians.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
Aesthetic, Cosmetic, Post-inflammatory hyperpigmentation (PIH)

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Topical cream for PIH
Arm Type
Other
Arm Description
The topical cream contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract.
Intervention Type
Other
Intervention Name(s)
Topical cream Z for PIH
Intervention Description
The topical cream Z contain combination of niacinamide, arbutin, Scutellaria Baicalensis Root Extract, Centella Asiatica Extract and Camellia Sinensis Leaf Extract. Participants will used the topical cream twice daily for 20 weeks
Primary Outcome Measure Information:
Title
Change in skin spot level
Description
Skin spot will be assessed using JANUS III skin analyzer.
Time Frame
Baseline, week 4, week 8, week 12, week 16 and week 20.
Title
Change in hyperpigmentation score
Description
The hyperpigmented skin area will be assessed based on Modified Melasma Area and Severity Index (mMASI) Score. Scoring system of mMASI score: A, Area of involvement is rated from 0 to 6: (0 indicates absent, 1=<10%, 2= 10% to 90%, 3= 30%-49%, 4= 50%-69%, 5= 70% to 89%, 6=90% to 100%). D, Darkness is rated from 0 to 4: 0= absent, 1=slight hyperpigmentation, 2= mild hyperpigmentation, 3= marked hyperpigmentation, 4=severe hyperpigmentation. Total mMASI score range is 0 (clear) to 24 (most severe melasma) and calculated by adding scores (A and D) for 4 areas of the face. The formula for mMASI score = 0.3×A(forehead)×D (forehead)+0.3×A (left malar) ×D (left malar) + 0.3×A(right malar)×D (right malar)+0.1×A(chin)×D (chin).
Time Frame
Baseline, week 4, week 8, week 12, week 16 and week 20.
Title
Adverse effect after using the topical cream.
Description
Based on adverse effect occurrence on participants that occur during study period (20 weeks)
Time Frame
Week 20
Secondary Outcome Measure Information:
Title
Participant satisfaction after using the topical cream for 20 weeks.
Description
Participation satisfaction will be evaluated using the Physician Global Assessment (PGA) survey. The subjective score of changes in skin conditions including skin wrinkles, dryness, smoothness, moisturizing and brightening effect will be graded as follows: very satisfied, satisfied, neutral, dissatisfied, very dissatisfied.
Time Frame
Week 20

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Malaysia citizen Healthy adult, aged between 18 to 40 years old. Participants who have post-inflammatory hyperpigmentation on skin Exclusion Criteria: Participants with skin disorders such as skin infection or skin inflammation. Participants who have undergone any skin and cosmetic treatments such as dermal fillers, botox, laser, chemical peels within the last 3 months. Participant who is taking isotretinoin for the past 6 or 12 months and immunocompromised patients. Pregnant, breastfeeding women or planned for pregnancy during the study period.
Facility Information:
Facility Name
Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre
City
Petaling Jaya
State/Province
Selangor
ZIP/Postal Code
47810
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
SITI NUR HANIS MAMOOD
Phone
+60167572670
Email
hanis@usmari.org.my
First Name & Middle Initial & Last Name & Degree
Nur Izzati Abdul Rashid
Phone
+60167252670
Email
izzati@usmari.org.my

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Efficacy of Topical Cream for Post-inflammatory Hyperpigmentation Skin Among Malaysians

We'll reach out to this number within 24 hrs